|
HUE039908T2
(hu)
*
|
2009-02-02 |
2019-02-28 |
Glaxosmithkline Biologicals Sa |
Majom adenovírusból származó nukleinsav- és aminosav-szekvenciák, azt tartalmazó vektorok és alkalmazásuk
|
|
EA201270607A1
(ru)
|
2009-11-09 |
2012-09-28 |
Генвек, Инк. |
Аденовирус обезьян и способы его использования
|
|
EP2560680B1
(en)
*
|
2010-04-16 |
2018-11-28 |
The Government of the United States of America as represented by the Secretary of the Department of Health and Human Services |
Chimpanzee adenoviral vector-based filovirus vaccines
|
|
WO2012071318A2
(en)
*
|
2010-11-23 |
2012-05-31 |
The Trustees Of The University Of Pennsylvania |
Subfamily e simian adenoviruses a1321, a1325, a1295, a1309, a1316 and a1322 and uses thereof
|
|
WO2012089231A1
(en)
|
2010-12-30 |
2012-07-05 |
Okairòs Ag |
Paramyxovirus vaccines
|
|
TWI623618B
(zh)
|
2011-07-12 |
2018-05-11 |
傳斯堅公司 |
Ｈｂｖ聚合酶突變體
|
|
WO2013045658A1
(en)
|
2011-09-29 |
2013-04-04 |
Transgene Sa |
Immunotherapy composition and regimen for treating hepatitis c virus infection
|
|
WO2013045668A2
(en)
|
2011-09-29 |
2013-04-04 |
Transgene Sa |
Immunotherapy composition and regimen for treating hepatitis c virus infection
|
|
EP2764012B1
(en)
*
|
2011-10-05 |
2022-02-23 |
GenVec, Inc. |
Adenoviral vectors and methods of use
|
|
WO2013052832A2
(en)
|
2011-10-05 |
2013-04-11 |
Genvec, Inc. |
Adenoviral vectors and methods of use
|
|
US9629906B2
(en)
|
2011-10-05 |
2017-04-25 |
Genvec, Inc. |
Affenadenovirus (gorilla) or adenoviral vectors and methods of use
|
|
WO2013074501A1
(en)
|
2011-11-14 |
2013-05-23 |
Crucell Holland B.V. |
Heterologous prime-boost immunization using measles virus-based vaccines
|
|
US8932607B2
(en)
|
2012-03-12 |
2015-01-13 |
Crucell Holland B.V. |
Batches of recombinant adenovirus with altered terminal ends
|
|
JP5770952B2
(ja)
|
2012-03-12 |
2015-08-26 |
クルセル ホランド ベー ヴェー |
改変末端を有する組換えアデノウイルスのバッチ
|
|
AU2013255511B2
(en)
|
2012-05-04 |
2016-01-28 |
Pfizer Inc. |
Prostate-associated antigens and vaccine-based immunotherapy regimens
|
|
WO2013173702A2
(en)
*
|
2012-05-18 |
2013-11-21 |
The Trustees Of The University Of Pennsylvania |
Subfamily e simian adenoviruses a1302, a1320, a1331 and a1337 and uses thereof
|
|
EP2855511B1
(en)
|
2012-05-29 |
2019-07-24 |
GenVec, Inc. |
Herpes simplex virus vaccine
|
|
HRP20211756T1
(hr)
|
2012-07-05 |
2022-02-18 |
Glaxosmithkline Biologicals Sa |
Novi senzibilizacijsko-pojačivački režimi koji uključuju imunogene polipeptide koje kodiraju polinukleotidi
|
|
WO2014005643A1
(en)
|
2012-07-05 |
2014-01-09 |
Okairos Ag |
Novel prime-boosting regimens involving immunogenic polypeptides encoded by polynucleotides
|
|
EP4631509A3
(en)
|
2012-11-16 |
2026-03-04 |
Beth Israel Deaconess Medical Center, Inc. |
Recombinant adenoviruses and use thereof
|
|
AU2014236207B2
(en)
|
2013-03-14 |
2019-05-23 |
Salk Institute For Biological Studies |
Oncolytic adenovirus compositions
|
|
WO2014139587A1
(en)
|
2013-03-15 |
2014-09-18 |
Okairòs Ag |
Improved poxviral vaccines
|
|
JP6469081B2
(ja)
|
2013-04-25 |
2019-02-13 |
ヤンセン ファッシンズ アンド プリベンション ベーフェーＪａｎｓｓｅｎ Ｖａｃｃｉｎｅｓ ＆ Ｐｒｅｖｅｎｔｉｏｎ Ｂ．Ｖ． |
安定化された可溶性融合前ｒｓｖｆポリペプチド
|
|
WO2015092710A1
(en)
|
2013-12-19 |
2015-06-25 |
Glaxosmithkline Biologicals, S.A. |
Contralateral co-administration of vaccines
|
|
CN106659777A
(zh)
|
2014-06-13 |
2017-05-10 |
葛兰素史密丝克莱恩生物有限公司 |
免疫原性组合产品
|
|
HUE065565T2
(hu)
|
2014-09-03 |
2024-06-28 |
Bavarian Nordic As |
Módszerek és készítmények filovírus fertõzés elleni védõ immunitás elõidézésére
|
|
MX2017002890A
(es)
|
2014-09-03 |
2017-11-13 |
Bavarian Nordic As |
Métodos y composiciones para potenciar respuestas inmunitarias.
|
|
WO2017025782A1
(en)
|
2014-09-17 |
2017-02-16 |
Glaxosmithkline Biologicals Sa |
Improved poxviral vaccines
|
|
KR20250081944A
(ko)
|
2014-09-24 |
2025-06-05 |
솔크 인스티튜트 포 바이올로지칼 스터디즈 |
종양 살상 바이러스 및 이의 사용방법
|
|
ES2865150T3
(es)
|
2014-09-26 |
2021-10-15 |
Beth Israel Deaconess Medical Ct Inc |
Métodos y composiciones para inducir inmunidad protectora contra la infección por el virus de la inmunodeficiencia humana
|
|
ES3011733T3
(en)
|
2015-02-13 |
2025-04-08 |
Transgene |
Immunotherapeutic vaccine and antibody combination therapy
|
|
WO2016131945A1
(en)
|
2015-02-20 |
2016-08-25 |
Transgene Sa |
Combination product with autophagy modulator
|
|
WO2016166088A1
(en)
|
2015-04-14 |
2016-10-20 |
Janssen Vaccines & Prevention B.V. |
Recombinant adenovirus expressing two transgenes with a bidirectional promoter
|
|
KR20180004820A
(ko)
|
2015-05-15 |
2018-01-12 |
큐어백 아게 |
적어도 하나의 mRNA 구성의 투여를 포함하는 신규 프라임-부스트 요법
|
|
BE1024824B1
(fr)
*
|
2015-06-12 |
2018-07-13 |
Glaxosmithkline Biologicals Sa |
Polynucleotides et polypeptides d'adenovirus
|
|
CN107921118B
(zh)
*
|
2015-06-12 |
2022-11-08 |
葛兰素史密丝克莱恩生物有限公司 |
腺病毒多核苷酸和多肽
|
|
GB201514772D0
(en)
*
|
2015-08-19 |
2015-09-30 |
Glaxosmithkline Biolog Sa |
Adenovirus polynucleotides and polypeptides
|
|
CN107847581B
(zh)
|
2015-07-07 |
2022-03-22 |
扬森疫苗与预防公司 |
稳定化的可溶性融合前rsv f多肽
|
|
ES2839880T3
(es)
|
2015-07-07 |
2021-07-06 |
Janssen Vaccines & Prevention Bv |
Vacuna contra el VRS
|
|
GB201513176D0
(en)
*
|
2015-07-27 |
2015-09-09 |
Glaxosmithkline Biolog Sa |
Novel methods for inducing an immune response
|
|
PT3390430T
(pt)
|
2015-12-15 |
2019-11-20 |
Janssen Vaccines & Prevention Bv |
Antígenos, vetores, composições para o vírus da imunodeficiência humana e métodos da sua utilização
|
|
TWI709647B
(zh)
|
2016-01-19 |
2020-11-11 |
美商輝瑞股份有限公司 |
癌症疫苗
|
|
WO2017147265A1
(en)
|
2016-02-23 |
2017-08-31 |
Salk Institute For Biological Studies |
High throughput assay for measuring adenovirus replication kinetics
|
|
EP4155411A1
(en)
|
2016-02-23 |
2023-03-29 |
Salk Institute for Biological Studies |
Exogenous gene expression in therapeutic adenovirus for minimal impact on viral kinetics
|
|
EP3436591B1
(en)
|
2016-03-31 |
2023-01-04 |
The European Molecular Biology Laboratory |
Adenoviral coat protein derived delivery vehicles
|
|
PH12022552125A1
(en)
|
2016-04-05 |
2023-04-12 |
Janssen Vaccines & Prevention Bv |
Stabilized soluble pre-fusion rsv f proteins
|
|
KR102500970B1
(ko)
|
2016-04-05 |
2023-02-17 |
얀센 백신스 앤드 프리벤션 비.브이. |
Rsv에 대한 백신
|
|
CA3023022A1
(en)
|
2016-05-04 |
2017-11-09 |
Transgene Sa |
Combination therapy with cpg tlr9 ligand
|
|
CN109154000B
(zh)
|
2016-05-12 |
2022-07-05 |
扬森疫苗与预防公司 |
有效和平衡的双向启动子
|
|
IL264119B2
(en)
|
2016-05-30 |
2023-04-01 |
Janssen Vaccines Prevention B V |
f proteins of rsv are stabilized before fusion
|
|
KR102307065B1
(ko)
|
2016-06-20 |
2021-09-30 |
얀센 백신스 앤드 프리벤션 비.브이. |
강력하고 균형 잡힌 양방향성 프로모터
|
|
GB2549809C
(en)
|
2016-06-23 |
2022-11-30 |
Univ Oxford Innovation Ltd |
Vector
|
|
EP3484507A1
(en)
|
2016-07-15 |
2019-05-22 |
Janssen Vaccines & Prevention B.V. |
Methods and compositions for inducing protective immunity against a marburg virus infection
|
|
WO2018011198A1
(en)
|
2016-07-15 |
2018-01-18 |
Janssen Vaccines & Prevention B.V. |
Methods and compositions for inducing protective immunity against a marburg virus infection
|
|
MX2019002178A
(es)
|
2016-08-23 |
2019-09-18 |
Glaxosmithkline Biologicals Sa |
Peptidos de fusion con antigenos enlazados a fragmentos cortos de cadena invariante (cd74).
|
|
EP3518966A1
(en)
|
2016-09-29 |
2019-08-07 |
GlaxoSmithKline Biologicals S.A. |
Compositions and methods of treatment of persistent hpv infection
|
|
GB201616904D0
(en)
|
2016-10-05 |
2016-11-16 |
Glaxosmithkline Biologicals Sa |
Vaccine
|
|
US20190328869A1
(en)
|
2016-10-10 |
2019-10-31 |
Transgene Sa |
Immunotherapeutic product and mdsc modulator combination therapy
|
|
GB201620968D0
(en)
|
2016-12-09 |
2017-01-25 |
Glaxosmithkline Biologicals Sa |
Adenovirus polynucleotides and polypeptides
|
|
CA3045976A1
(en)
*
|
2016-12-09 |
2018-06-14 |
Glaxosmithkline Biologicals Sa |
Chimpanzee adenovirus constructs with lyssavirus antigens
|
|
EP3532082A4
(en)
|
2016-12-12 |
2020-08-26 |
Salk Institute for Biological Studies |
SYNTHETIC ADENOVIRUS TUMOR TARGETING AND THEIR USES
|
|
GB201701239D0
(en)
*
|
2017-01-25 |
2017-03-08 |
Glaxosmithkline Biologicals Sa |
Novel formulation
|
|
CN110268061B
(zh)
|
2017-02-09 |
2024-07-16 |
扬森疫苗与预防公司 |
用于表达异源基因的有效的短启动子
|
|
US11173204B2
(en)
|
2017-04-06 |
2021-11-16 |
Janssen Vaccines & Prevention B.V. |
MVA-BN and Ad26.ZEBOV or Ad26.filo prime-boost regimen
|
|
MX2019013259A
(es)
|
2017-05-08 |
2020-01-13 |
Gritstone Oncology Inc |
Vectores de neoantigeno de alfavirus.
|
|
CA3062614A1
(en)
*
|
2017-05-10 |
2018-11-15 |
University Of Utah Research Foundation |
Compositions and methods of use of arc capsids
|
|
WO2018210871A1
(en)
|
2017-05-17 |
2018-11-22 |
Janssen Vaccines & Prevention B.V. |
Methods and compositions for inducing protective immunity against rsv infection
|
|
US11229692B2
(en)
|
2017-05-17 |
2022-01-25 |
Janssen Vaccines & Prevention B.V. |
Methods and compositions for inducing protective immunity against RSV infection
|
|
CN110958887B
(zh)
|
2017-06-15 |
2023-10-31 |
扬森疫苗与预防公司 |
编码hiv抗原的痘病毒载体及其使用方法
|
|
DK3649237T3
(da)
*
|
2017-07-05 |
2022-02-21 |
Nouscom Ag |
Nukleinsyre- og aminosyresekvenser fra ikke-humant menneskeabe-adenovirus, vektorer indeholdende samme og anvendelser deraf
|
|
PE20200613A1
(es)
|
2017-07-11 |
2020-03-11 |
Pfizer |
Composiciones inmunogenicas
|
|
JP7298926B2
(ja)
|
2017-07-12 |
2023-06-27 |
ノイスコム アーゲー |
癌の治療のためのネオアンチゲンワクチン組成物
|
|
WO2019016756A1
(en)
|
2017-07-21 |
2019-01-24 |
Glaxosmithkline Biologicals Sa |
ANTIGEN CONSTRUCTS OF CHIKUNGUNYA VIRUSES
|
|
JP7311489B2
(ja)
|
2017-07-28 |
2023-07-19 |
ヤンセン ファッシンズ アンド プリベンション ベーフェー |
異種ｒｅｐＲＮＡ免疫化のための方法および組成物
|
|
WO2019053109A1
(en)
|
2017-09-15 |
2019-03-21 |
Janssen Vaccines & Prevention B.V. |
METHOD FOR SAFE INDUCTION OF IMMUNITY AGAINST RSV
|
|
AU2018351308B2
(en)
|
2017-10-16 |
2021-12-02 |
Glaxosmithkline Biologicals Sa |
Replication competent adenoviral vectors
|
|
CA3084358A1
(en)
|
2017-10-16 |
2019-04-25 |
Glaxosmithkline Biologicals Sa |
Enhanced promoter
|
|
US20200299651A1
(en)
|
2017-10-16 |
2020-09-24 |
Glaxosmithkline Biologicals Sa |
Simian adenoviral vectors with two expression cassettes
|
|
CN111527213A
(zh)
|
2017-10-16 |
2020-08-11 |
葛兰素史密丝克莱恩生物有限公司 |
具有两个编码rsv抗原蛋白或片段的表达盒的腺病毒载体
|
|
WO2019086450A1
(en)
*
|
2017-10-31 |
2019-05-09 |
Janssen Vaccines & Prevention B.V. |
Adenovirus and uses thereof
|
|
WO2019086466A1
(en)
*
|
2017-10-31 |
2019-05-09 |
Janssen Vaccines & Prevention B.V. |
Adenovirus and uses thereof
|
|
MA50502A
(fr)
|
2017-10-31 |
2020-09-09 |
Janssen Vaccines & Prevention Bv |
Adénovirus et utilisations associées
|
|
BR112020008435A2
(pt)
|
2017-10-31 |
2020-11-17 |
Janssen Vaccines & Prevention B.V. |
vetores de adenovírus e seus usos
|
|
CA3078692A1
(en)
|
2017-11-03 |
2019-05-09 |
Nouscom Ag |
Vaccine t cell enhancer
|
|
BR112020007884A2
(pt)
|
2017-11-20 |
2020-11-03 |
Janssen Pharmaceuticals, Inc. |
método de proporcionar uma administração segura de vetores adenovirais que codificam um antígeno de vírus zika
|
|
WO2019118480A1
(en)
*
|
2017-12-11 |
2019-06-20 |
Beth Israel Deaconess Medical Center, Inc. |
Recombinant adenoviruses and uses thereof
|
|
GB201721068D0
(en)
|
2017-12-15 |
2018-01-31 |
Glaxosmithkline Biologicals Sa |
Hepatitis B immunisation regimen and compositions
|
|
GB201721069D0
(en)
|
2017-12-15 |
2018-01-31 |
Glaxosmithkline Biologicals Sa |
Hepatitis B Immunisation regimen and compositions
|
|
CN111741766A
(zh)
|
2017-12-19 |
2020-10-02 |
杨森科学爱尔兰无限公司 |
用于诱导针对乙型肝炎病毒(hbv)的免疫应答的方法和组合物
|
|
MX2020006225A
(es)
|
2017-12-20 |
2020-12-07 |
Glaxosmithkline Biologicals Sa |
Constructos antigenicos del virus de epstein-barr.
|
|
MX2020010499A
(es)
|
2018-04-09 |
2020-10-28 |
Salk Inst For Biological Studi |
Composiciones de adenovirus oncoliticas con propiedades aumentadas de replicacion.
|
|
JP2021526831A
(ja)
*
|
2018-06-12 |
2021-10-11 |
グラクソスミスクライン バイオロジカルズ ソシエテ アノニム |
アデノウイルスポリヌクレオチド及びポリペプチド
|
|
EP3581201A1
(en)
|
2018-06-15 |
2019-12-18 |
GlaxoSmithKline Biologicals S.A. |
Escherichia coli o157:h7 proteins and uses thereof
|
|
EP3587581A1
(en)
|
2018-06-26 |
2020-01-01 |
GlaxoSmithKline Biologicals S.A. |
Formulations for simian adenoviral vectors having enhanced storage stability
|
|
US11713469B2
(en)
|
2018-07-20 |
2023-08-01 |
Janssen Vaccines & Prevention B.V. |
Recombinant adenoviral vector expressing Zika antigen with improved productivity
|
|
GB201812647D0
(en)
*
|
2018-08-03 |
2018-09-19 |
Chancellor Masters And Scholars Of The Univ Of Oxford |
Viral vectors and methods for the prevention or treatment of cancer
|
|
KR20210081325A
(ko)
|
2018-10-19 |
2021-07-01 |
노우스콤 아게 |
경골어류 불변 사슬 암 백신
|
|
JP2022513025A
(ja)
|
2018-11-13 |
2022-02-07 |
ヤンセン ファッシンズ アンド プリベンション ベーフェー |
安定化された融合前ｒｓｖ ｆタンパク質
|
|
SG11202103243PA
(en)
|
2018-11-15 |
2021-04-29 |
Nouscom Ag |
Selection of cancer mutations for generation of a personalized cancer vaccine
|
|
TWI852977B
(zh)
|
2019-01-10 |
2024-08-21 |
美商健生生物科技公司 |
前列腺新抗原及其用途
|
|
TW202102256A
(zh)
|
2019-03-05 |
2021-01-16 |
比利時商葛蘭素史密斯克藍生物品公司 |
B型肝炎免疫法及組合物
|
|
CN113573741B
(zh)
*
|
2019-03-20 |
2024-07-26 |
国立大学法人北海道大学 |
修饰腺病毒和含有其的医药
|
|
MX2021014525A
(es)
*
|
2019-05-30 |
2022-03-17 |
Gritstone Bio Inc |
Adenovirus modificados.
|
|
WO2021092095A1
(en)
*
|
2019-11-04 |
2021-05-14 |
Gritstone Oncology, Inc. |
Neoantigen vaccine therapy
|
|
KR20220115569A
(ko)
|
2019-11-18 |
2022-08-17 |
얀센 바이오테크 인코포레이티드 |
돌연변이 calr 및 jak2에 기반한 백신 및 이의 용도
|
|
CN113088530A
(zh)
*
|
2020-01-08 |
2021-07-09 |
怡道生物科技(苏州)有限公司 |
一种基于黑猩猩ChAd63型腺病毒的表达载体及其构建方法
|
|
TW202204380A
(zh)
|
2020-01-31 |
2022-02-01 |
美商詹森藥物公司 |
用於預防及治療冠狀病毒感染之組合物及方法－sars-cov-2疫苗
|
|
TW202144388A
(zh)
|
2020-02-14 |
2021-12-01 |
美商健生生物科技公司 |
在卵巢癌中表現之新抗原及其用途
|
|
TW202144389A
(zh)
|
2020-02-14 |
2021-12-01 |
美商健生生物科技公司 |
在多發性骨髓瘤中表現之新抗原及其用途
|
|
EP4135757A1
(en)
|
2020-04-13 |
2023-02-22 |
Janssen Biotech, Inc. |
Psma and steap1 vaccines and their uses
|
|
MX2022014162A
(es)
|
2020-05-11 |
2023-02-23 |
Janssen Pharmaceuticals Inc |
Proteínas de fusión de la proteína de la espícula del coronavirus estabilizadas.
|
|
MX2023000024A
(es)
|
2020-06-29 |
2023-04-12 |
Janssen Vaccines & Prevention Bv |
Combinación vacunal contra la infección por el virus respiratorio sincicial.
|
|
CN113897388B
(zh)
*
|
2020-07-06 |
2024-05-31 |
嘉兴安宇生物科技有限公司 |
一种新型黑猩猩腺病毒载体及其构建方法和应用
|
|
US12295997B2
(en)
|
2020-07-06 |
2025-05-13 |
Janssen Biotech, Inc. |
Prostate neoantigens and their uses
|
|
EP4176087A1
(en)
|
2020-07-06 |
2023-05-10 |
Janssen Biotech, Inc. |
A method for determining responsiveness to prostate cancer treatment
|
|
WO2022009049A1
(en)
|
2020-07-06 |
2022-01-13 |
Janssen Biotech, Inc. |
Prostate neoantigens and their uses
|
|
JP2023532369A
(ja)
|
2020-07-06 |
2023-07-27 |
ヤンセン ファーマシューティカルズ，インコーポレーテッド |
安定化されたコロナウイルススパイクタンパク質融合タンパク質
|
|
CN116367854A
(zh)
|
2020-07-08 |
2023-06-30 |
杨森科学爱尔兰无限公司 |
针对hbv的rna复制子疫苗
|
|
TW202217002A
(zh)
|
2020-07-13 |
2022-05-01 |
法商傳斯堅公司 |
免疫抑制之治療
|
|
KR20230046313A
(ko)
*
|
2020-08-06 |
2023-04-05 |
그릿스톤 바이오, 인코포레이티드 |
다중에피토프 백신 카세트
|
|
US12275766B2
(en)
|
2020-12-23 |
2025-04-15 |
Janssen Biotech, Inc. |
Neoantigen peptide mimics
|
|
WO2022175477A1
(en)
|
2021-02-19 |
2022-08-25 |
Janssen Vaccines & Prevention B.V. |
Stabilized pre-fusion rsv fb antigens
|
|
WO2022175479A1
(en)
|
2021-02-19 |
2022-08-25 |
Janssen Vaccines & Prevention B.V. |
Vaccine combinations against respiratory syncytial virus strain a and b infections
|
|
KR20230165275A
(ko)
|
2021-04-01 |
2023-12-05 |
얀센 백신스 앤드 프리벤션 비.브이. |
안정화된 융합 전 piv3 f 단백질
|
|
WO2022218997A1
(en)
|
2021-04-12 |
2022-10-20 |
Centre National De La Recherche Scientifique (Cnrs) |
Novel universal vaccine presenting system
|
|
EP4358998A1
(en)
|
2021-06-21 |
2024-05-01 |
Nouscom AG |
Vaccine composition comprising encoded adjuvant
|
|
WO2023020939A1
(en)
|
2021-08-17 |
2023-02-23 |
Janssen Pharmaceuticals, Inc. |
Sars-cov-2 vaccines
|
|
WO2023026182A1
(en)
|
2021-08-24 |
2023-03-02 |
Janssen Pharmaceuticals, Inc. |
Sars-cov-2 vaccines
|
|
WO2023047349A1
(en)
|
2021-09-24 |
2023-03-30 |
Janssen Pharmaceuticals, Inc. |
Stabilized coronavirus spike protein fusion proteins
|
|
WO2023047348A1
(en)
|
2021-09-24 |
2023-03-30 |
Janssen Pharmaceuticals, Inc. |
Stabilized corona virus spike protein fusion proteins
|
|
WO2023111725A1
(en)
|
2021-12-14 |
2023-06-22 |
Janssen Pharmaceuticals, Inc. |
Sars-cov-2 vaccines
|
|
EP4448802A1
(en)
|
2021-12-16 |
2024-10-23 |
Janssen Vaccines & Prevention B.V. |
Stabilized pre-fusion hmpv fusion proteins
|
|
WO2023198815A1
(en)
|
2022-04-14 |
2023-10-19 |
Janssen Vaccines & Prevention B.V. |
Sequential administration of adenoviruses
|
|
WO2023213764A1
(en)
|
2022-05-02 |
2023-11-09 |
Transgene |
Fusion polypeptide comprising an anti-pd-l1 sdab and a member of the tnfsf
|
|
WO2024061757A1
(en)
|
2022-09-23 |
2024-03-28 |
Janssen Vaccines & Prevention B.V. |
Pre-fusion human piv1 f proteins
|
|
WO2024061759A1
(en)
|
2022-09-23 |
2024-03-28 |
Janssen Vaccines & Prevention B.V. |
Stabilized coronavirus s proteins
|
|
CN120344553A
(zh)
|
2022-10-06 |
2025-07-18 |
Msd国际商务股份有限公司 |
稳定的融合前piv3 f蛋白
|
|
WO2025158316A1
(en)
|
2024-01-26 |
2025-07-31 |
Janssen Biotech, Inc. |
Ovarian neoantigens and use thereof
|